↑ 薬物リストへ　← 戻る

Selexipag, act-293987 (ns-304)    (DrugBank: Selexipag)

5 diseases
告示番号疾患名（ページ内リンク）臨床試験数
51全身性強皮症0
70広範脊柱管狭窄症0
84サルコイドーシス0
86肺動脈性肺高血圧症3
88慢性血栓塞栓性肺高血圧症0

51. 全身性強皮症　［臨床試験数：466，薬物数：536（DrugBank：142），標的遺伝子数：110，標的パスウェイ数：210］
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 466 trial found

70. 広範脊柱管狭窄症　［臨床試験数：91，薬物数：195（DrugBank：54），標的遺伝子数：60，標的パスウェイ数：85］
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 91 trial found

84. サルコイドーシス　［臨床試験数：143，薬物数：221（DrugBank：79），標的遺伝子数：82，標的パスウェイ数：165］
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 143 trial found

86. 肺動脈性肺高血圧症　［臨床試験数：1,083，薬物数：667（DrugBank：122），標的遺伝子数：98，標的パスウェイ数：185］
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 1,083 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-006453-12-AT
(EUCTR)		19/03/200923/06/2008Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertensionA multi-centre, multinational, open-label study to evaluate the long-term safety, tolerability and efficacy of selexipag / ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over (open-extension study to NS 304/-02) Pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use
MedDRA version: 19.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Product Code: Selexipag, ACT-293987 (NS-304)
INN or Proposed INN: Selexipag		Actelion Pharmaceuticals Ltd.NULLNot RecruitingFemale: yes
Male: yes		40Phase 2France;Hungary;Belgium;Austria;Germany;Italy;United Kingdom
2EUCTR2007-006453-12-BE
(EUCTR)		03/10/200807/07/2008Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertensionA multi-centre, multinational, open-label study to evaluate the long-term safety, tolerability and efficacy of selexipag / ACT 293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over (open-extension study to NS 304/-02) pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use
MedDRA version: 18.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Product Code: Selexipag, ACT-293987 (NS-304)
INN or Proposed INN: Selexipag		Actelion Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes		40Phase 2France;Hungary;Belgium;Austria;Germany;Italy;United Kingdom
3EUCTR2007-006453-12-DE
(EUCTR)		12/09/200819/12/2008Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertensionA multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of selexipag / ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over (open-extension study to NS-304/-02) Pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use
MedDRA version: 18.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Product Code: Selexipag, ACT-293987 (NS-304)
INN or Proposed INN: Selexipag		Actelion Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes		40Phase 2France;Hungary;Belgium;Austria;Germany;Italy;United Kingdom

88. 慢性血栓塞栓性肺高血圧症　［臨床試験数：145，薬物数：112（DrugBank：22），標的遺伝子数：13，標的パスウェイ数：52］
Searched query = "Chronic thromboembolic pulmonary hypertension", "CTEPH", "Idiopathic chronic pulmonary thromboembolism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 145 trial found